

AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

UCITS

Asset Management Company
Amundi Asset Management

Copany's shares accounting management sub-delegate
CACEIS Fund Administration France

Custodian
CACEIS BANK

Statutory auditor
PRICEWATERHOUSECOOPERS AUDIT

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Contents

	Pages
Informations about the Fund	3
Annual Report	8
Significant events during the financial period	14
Specific details	16
Regulatory informations	17
Auditor's Certification	20
Annual accounts	26
Balance Sheet Asset	27
Balance Sheet Liabilities	28
Off-balance sheet	29
Income Statement	30
Notes to the annual accounts	31
Accounting rules and methods	32
Changes in net assets	35
Table of profit (loss) of the fund over the past five financial periods	42
Portfolio Listing	43

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Informations about the Fund

Classification

International equities.

Determination and allocation of distributable sums

Accumulation and/or distribution at the discretion of the Management Company.

Tax treatment

The Fund is eligible for the Plan d'Epargne en Actions ("PEA" reserved for French investors) and life insurance policies. The Fund may provide a support vehicle for life insurance policies denominated in units of account.

The UCITS, by its nature, is not subject to taxation. However, unitholders may be taxed on any income distributed by the Fund or when they sell Fund units. The tax treatment applicable to amounts distributed by the Fund or unrealised or realised capital gains or losses will depend on the individual unitholder's tax situation, residence for tax purposes and/or the investment jurisdiction of the Fund. If an investor is uncertain of his or her tax position, the investor should consult a financial advisor or a professional investment consultant to determine the tax rules applicable to his or her particular situation before any investment. Some income distributed by the UCITS to unitholders residing outside France may be subject to withholding tax in France.

Germany: at least 90% of the Fund will be permanently invested in listed shares. For the purposes of interpreting this ratio, shares issued by REITs (as defined by the German Ministry of Finance) or UCIs are not considered as shares.

Benchmark index

The Fund's benchmark index is the USD-denominated, euro-adjusted MSCI Europe Health Care Index with net dividends reinvested (net return).

The MSCI Europe Health Care Index is an "equities" index calculated and published by the international index supplier MSCI Inc. ("MSCI"). Equities constituting the MSCI Europe Health Care Index are taken from a portfolio of European companies in the health care sector.

Management fees & commissions

Subscription and redemption fees for any unit category: 0.25%.

Subscription fees received by the Fund: None.

In compliance with current regulations, this mutual fund has, during the financial period just ended, levied charges at rates which are in line with those stated in the Prospectus and set out in the paragraph "Management Fees" and use under the following headings:

- Notes to the annual accounts/Management fees.
- Further Details/Subscription and/or redemption fees/Management fees.

Investment objective

The Fund's investment objective is to track as closely as possible the MSCI Europe Health Care Index (see section "Benchmark index"), whether said index rises or falls.

The Fund is managed so as to achieve a gap between changes in its NAV and changes in the value of the euro-adjusted MSCI Europe Health Care Index (referred to below as the "MSCI Europe Health Care Index") as small as possible. The target for maximum tracking error between the Fund's NAV and the value of the euro-adjusted MSCI Europe Health Care Index is 2%.

If the "tracking error" exceeds 2%, the objective would nevertheless be to remain below 15% of the volatility of the euro-adjusted MSCI Europe Health Care Index.

Investment strategy

The Fund is managed by "index tracking".

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

1. Strategy employed:

The Fund is managed using a technique known as "index-tracking", the objective of which is to replicate changes in the performance of the MSCI Europe Health Care Index using a synthetic replication method.

To maintain the closest possible correlation with the performance of the MSCI Europe Health Care Index, the Fund will buy a diversified portfolio of stocks (the "Portfolio") and an over-the-counter (OTC) total return swap, a financial derivative instrument which turns the exposure to the securities in the Portfolio into exposure to the MSCI Europe Health Care Index.

The Fund shall observe the investment rules stipulated in Articles R214-21, R214-22 and R214-23 the French Monetary and Financial Code.

The Portfolio comprising directly held assets described in the "Assets used" section, complies with the provisions of Article R 214-21 of the French Monetary and Financial Code (CMF).

The Fund's exposure to the Index achieved through the total return swap may be eligible for exemption ratios applicable to the index-tracking UCITS referred to in Article R214-22 of the French Monetary and Financial Code (CMF). That Article stipulates that an index may comprise up to 20% equities or debt securities issued by the same entity; this limit may be raised to 35% maximum for a single issuing entity, when such increase is justified by special market circumstances such as the regulated markets where some marketable securities or some money-market instruments are largely dominant.

2. Assets used (except embedded derivatives):

The Fund's exposure to the Index is achieved through the total return swap.

The Portfolio consists of the Fund's directly held assets described below.

Equities:

At least 60% of the Fund will be permanently exposed to a foreign equity market or equity markets in a number of countries, including the French market when appropriate.

Up to 100% of the Fund's net assets will be invested, subject to the legal and regulatory ratios, in international equities (any economic sector, traded on any market).

The stocks in the Fund's portfolio will consist of stocks included in the MSCI Europe Health Care Index and other international stocks, from all economic sectors, including small-cap markets. The equities in the Fund's assets will be chosen to limit costs associated with reproducing the MSCI Europe Health Care Index.

Over 75% of the portfolio's value will, at all times, consist of stocks of companies registered in a Member State of the European Union, or in another State which is part of the European Economic Area (EEA) and has signed a tax convention with France that provides for administrative assistance to prevent fraud and tax evasion. This minimum level of equity exposure makes the Fund eligible for a Plan d'Épargne en Actions (French Stock Savings Plan – PEA).

At least 90% of the Fund will be permanently invested in listed shares. For the purposes of interpreting this ratio, shares issued by REITs (as defined by the German Ministry of Finance) or UCIs are not considered as shares.

Interest-rate instruments:

Interest-rate instruments: Up to 25% of the Fund's net assets may be invested in any kind of bond instruments.

Portfolio securities will be selected according to the best judgement of the management and in compliance with the Management Company's internal credit risk monitoring policy.

For the purpose of stock-picking, management does not - neither exclusively nor automatically - rely on the ratings issued by rating agencies, but bases its buy and sell opinion about a security on its own credit and market analyses. For information, management may specifically deal in securities with minimum ratings, at the time of purchase, of BBB- in the S&P and Moody's scale ("investment grade" rating).

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

The bond issuers selected may be from the private sector or from the public sector (national or local governments, etc.), and private sector debt may account for up to 100% of all debt instruments. Foreign debt instruments will be denominated in the currency of one of the OECD member countries.

In order to meet its investment objective and/or manage intermediate financial flows, the Fund may hold up to 10% of its assets in the following:

Debt instruments and money market instruments in euros:

Cash flow will be managed through money market instruments.

Portfolio securities will be selected according to the best judgement of the management and in compliance with the Management Company's internal credit risk monitoring policy.

For the purpose of stock-picking, management does not - neither exclusively nor automatically - rely on the ratings issued by rating agencies, but bases its buy and sell opinion about a security on its own credit and market analyses. For information, management may specifically deal in securities with minimum ratings of AA in the S&P and Moody's scale.

The bond issuers selected may be from the private sector or from the public sector (national or local governments, etc.), and private sector debt may account for up to 100% of all debt instruments. The average maturity of these instruments will not exceed 10 years.

UCITS units or shares:

The Fund may hold up to 10% of its assets in units and/or shares of UCITS. These UCITS are representative of all asset classes, in compliance with the Fund's requirements.

They may be UCITS managed by the Management Company, or by other entities, which may or may not belong to the Crédit Agricole SA Group, including related companies.

3. Derivatives:

The Fund will use OTC derivative financial instruments, in particular futures such as total return swaps, to swap the value of stocks held by the Fund for the value of the MSCI Europe Health Care Index.

The Fund may take positions in the following derivatives:

- Type of market:

- ☒ regulated
- ☒ organised
- ☒ over-the-counter

- Categories of risk in which the Fund intends to take a position:

- ☒ equity risk
- ☐ interest rate risk
- ☒ currency risk
- ☐ credit risk
- ☐ other risks

- Nature of positions to be taken, which must be limited to those required to meet the management objective:

- ☒ hedging
- ☒ exposure
- ☐ arbitrage
- ☐ other

- Types of instruments used:

- ☒ futures: on equities and indices
- ☒ options: on equities and indices
- ☒ total return swaps: on equities and indices

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

The Fund may enter into exchange contracts in two combinations from the following types of flows:

- fixed rate
- variable rate (indexed on the Eonia, Euribor, or any other market benchmark)
- performance linked to one or more listed currencies, equities, stock market indices or securities, UCIs or investment funds
- dividends (net or gross)
- ☒ total return swap
- ☐ credit derivatives: credit default swaps
- ☐ other

- Strategies for use of incorporated derivatives to achieve the management objective:

- ☒ constructing synthetic exposure to a particular security, sector and/or to the MSCI Europe Health Care Index via the use of swaps.
- ☒ management of intermediate cash flows (dividends, subscriptions/redemptions, etc.) to reach the desired degree of exposure to a particular stock and/or sector and/or to the MSCI Europe Health Care Index via the use of futures.
- ☒ management of intermediate cash flows (dividends, subscriptions/redemptions, etc.) to reach the desired degree of exposure to a particular stock and/or sector and/or to the MSCI Europe Health Care Index via the use of options.

These instruments may be used to hedge up to 100% of the Fund's net assets.

For information purposes, when the Fund is being set up, total return swaps represent approximately 100% of net assets and they represent up to 110% during its life cycle.

The assets held by the Fund and on the performance of which the total return swaps focus are retained by the depositary.

The forward total return swap is kept in position in the depositary's books.

4. Securities incorporating derivatives ("embedded derivatives"):

None.

5. Deposits and liquid assets:

The Fund may hold up to 20% of its net assets in deposits for a maximum term of twelve months. The deposits are used for cash management purposes and help the Fund achieve its management objectives.

6. Borrowing:

The Fund may temporarily, and in exceptional cases, borrow up to 10% of its net assets in order to optimise its cash-flow management.

7. Temporary acquisitions and sales of securities:

None.

Over-exposure of the assets: None.

Total exposure to risks arising from these commitments and from open positions in real securities shall not exceed 110% of net assets.

Information relating to financial guarantees (temporary purchases and sales of securities) and total return swaps (TRS):

Type of collateral:

In the context of temporary purchases and sales of securities and OTC derivative transactions, the Fund may receive collateral of securities and cash.

The discounts that may be applied to the collateral received will take into account the nature, maturity, credit quality, currency and price volatility of the securities, as well as the results of the stress tests performed.

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

The securities received as collateral must adhere to the criteria defined by the Management Company. They must be:

- liquid
- transferable at any time
- diversified in compliance with the eligibility, exposure and diversification rules of the UCITS
- issued by an issuer that is not an entity of the counterparty or its group

For bonds, the securities will also be issued by high-quality issuers located in the OECD whose minimum rating may be AAA to BBB- on the scale of Standard & Poor's or with a rating deemed equivalent by the management company. Bonds must have a maximum maturity of 50 years.

The criteria described above are detailed in a Risk Policy available on the Management Company's website at www.amundi.com and may be subject to changes, particularly in the event of exceptional market circumstances.

The discounts that may be applied to the collateral received will take into account the credit quality, the price volatility of the securities and the results of the stress tests performed.

Reuse of cash received as collateral: Cash received as collateral may be reinvested in deposits, government bonds, repurchase agreements or short-term money market UCITS in accordance with the Management Company's Risk Policy.

Reuse of securities received as collateral:

Not authorised: Securities received as collateral may not be sold, reinvested or provided as collateral.

Overview of the procedure for choosing intermediaries / counterparties and comments

The Management Company generally issues a bid tender. In this case, a comprehensive Request For Proposal ("RFP") (total return swap and market making) was issued for a portion of the AMUNDI ETF Fund product line.

For this reason, neither the Management Company nor the Delegated Fund Manager have undertaken or shall undertake, for this particular Fund, a formal competitive bidding procedure that can be tracked and monitored among counterparties for OTC derivative financial instruments, as the counterparty has already been selected during the comprehensive RFP. The Fund may carry out these transactions with BNP Paribas SA or any other Company of the BNP Paribas SA group as counterparties or intermediaries.

Risk profile

Equity risk

Capital risk

Factors that may influence the ability of the Fund to track the performance of the MSCI Europe Health Care

Index

Credit risk

Sector / industry risk

Credit risk

Counterparty risk related to the tracking method selected

Legal risk

Liquidity risk

Liquidity risk in a stock market

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Annual Report

Mars 2019

The funds objective is to track the MSCI Europe Health Care index while remaining eligible for the PEA (i.e. the fund undertakes to hold 75% of its assets in PEA-eligible equities at all times). It therefore holds a basket of shares and a performance swap which turns the Funds equity exposure into an exposure to the MSCI Europe Health Care.

For the period under review, the portfolio AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF performance is 18.60%. The benchmark performance is 18.91% with a tracking error of 0.06%.

Past performance is no guarantee of future performance.

Movements in portfolio listing during the period

Securities	Movements (in amount)	
	Acquisitions	Transfers
BAYER	10,601,676.95	9,947,193.22
ROYAL PHILIPS	7,045,809.33	6,590,375.70
BASF SE	6,789,338.35	6,360,923.95
ASML HOLDING NV	4,425,490.60	4,464,202.03
VOLKSWAGEN AG-PREF	5,087,479.04	3,311,078.68
SAP SE	3,713,526.20	3,809,824.70
BMW BAYERISCHE MOTOREN WERKE	3,064,256.32	4,079,186.74
ANHEUSER BUSCH INBEV SA/NV	3,474,017.87	3,098,621.21
NESTLE NOM.	4,992,765.39	1,534,114.59
BANCO DE BILBAO VIZCAYA S.A.	3,281,874.17	2,861,282.85

Efficient portfolio management (EPM) techniques and Financial derivative instruments

a) Exposure obtained through the EPM techniques and Financial derivative instruments

- Exposure obtained through the EPM techniques and Financial derivative instruments :
 - **Securities lending :**
 - **Securities loans :**
 - **Reverse repurchase agreement :**
 - **Repurchase :**
- Underlying exposure reached through financial derivative instruments : **32,368,009.80**
 - **Forward transaction :**
 - **Future :**
 - **Options :**
 - **Swap : 32,368,009.80**

b) Identity of the counterparty(ies) to EPM techniques and Financial derivative instruments

Identity of the counterparty(ies) to EPM techniques	Financial derivative instruments (*)
	BNP PARIBAS FRANCE

(*) Excepted derivative listed.

c) Type and amount of collateral received by the UCITS to reduce counterparty risk

Types of financial instruments	Amount portfolio currency
EPM . Term Deposit . Equities . Bonds . UCITS . Cash (**) Total	
Financial derivative instruments . Term Deposit . Equities . Bonds . UCITS . Cash Total	

(**) The cash account also includes liquidity resulting from repurchase deals.

d) Revenues and operational cost/fees from EPM

Revenues and operational cost/fees	Amount portfolio currency
. Revenues (***) . Other revenues Total revenues . Direct operational fees . Indirects operational fees . Other fees Total fees	

(***) Revenues received from loans, repurchase and reverse repurchase agreements.

Transparency of securities financing transactions and of reuse (SFTR) – Regulation SFTR – in accounting currency of the portfolio (EUR)

	Securities lending	Securities loan	Repurchase	Reverse repurchase agreement	Total Return Swaps (TRS)
--	--------------------	-----------------	------------	------------------------------	--------------------------

a) Securities and commodities on loan

Amount					
% of Net Assets*					

*% excluding cash and cash equivalent

b) Assets engaged in each type of SFTs and TRS expressed in absolute amount

Amount					32,368,009.80
% of Net Assets					90.76%

c) 10 largest collateral issuers received (excluding cash) across all SFTs and TRS

--	--	--	--	--	--

d) Top 10 counterparties expressed as an absolute amount of assets and liabilities without clearing

BNP PARIBAS FRANCE FRANCE					32,368,009.80
------------------------------	--	--	--	--	---------------

e) Type and quality (collateral)

Type					
Currency of the collateral					

f) Settlement and clearing

Tri-party				X	
Central Counterparty					
Bilateral	X			X	

	Securities lending	Securities loan	Repurchase	Reverse repurchase agreement	Total Return Swaps (TRS)
--	-----------------------	--------------------	------------	------------------------------------	-----------------------------

g) Maturity tenor of the collateral broken down maturity buckets

< 1 day					
[1 day - 1 week]					
]1 week - 1 month]					
]1 month - 3 months]					
]3 months - 1 year]					
> 1 year					
Open					

h) Maturity tenor of the SFTs and TRS broken down maturity buckets

< 1 day					
[1 day - 1 week]					
]1 week - 1 month]					
]1 month - 3 months]					
]3 months - 1 year]					
> 1 year					32,368,009.80
Open					

i) Data on reuse of collateral

Maximum amount (%)					
Amount reused (%)					
Cash collateral reinvestment returns to the collective investment undertaking in euro					

j) Data on safekeeping of collateral received by the collective investment undertaking

Caceis Bank					
Securities					
Cash					

k) Data on safekeeping of collateral granted by the collective investment undertaking

Securities					
Cash					

	Securities lending	Securities loan	Repurchase	Reverse repurchase agreement	Total Return Swaps (TRS)
--	-----------------------	--------------------	------------	------------------------------------	-----------------------------

l) Data on return and cost broken down

Revenus					
- OPC					
- Gestionnaire					
- Tiers					
Coûts					
- OPC					
- Gestionnaire					
- Tiers					

e) Type and quality (collateral)

Amundi Asset Management undertakes to accept only securities of a high credit quality and to increase the value of its collateral by applying valuation discounts to securities loaned to it. This process is regularly reviewed and updated.

i) Data on reuse of collateral

The regulations governing UCITS forbid the reuse of collateral securities. Cash collateral received is: reinvested in short-term money market funds (as defined by ESMA in its 'Guidelines on ETFs and other UCITS issues');

placed on deposit;

reinvested in high-quality long-term government bonds;

reinvested in high-quality short-term government bonds; or

used for the purpose of reverse repurchase transactions.

The maximum proportion of received collateral that may be reused is 0% in the case of securities and 100% in the case of cash.

The effective usage amounts to 0% for collateral securities and 100% for cash collateral.

k) Data on safekeeping of collateral granted by the collective investment undertaking

Amundi Asset Management undertakes to do business with a limited number of depositaries, selected to ensure the adequate custody of securities received and cash.

l) Data on return and cost broken down

For securities lending transactions and repurchase agreements, Amundi Asset Management has entrusted Amundi Intermédiation, acting on behalf of the UCITS, with the following responsibilities: selecting counterparties, ordering the implementation of market agreements, monitoring counterparty risk, performing qualitative and quantitative monitoring of collateralisation (dispersion checks, ratings, liquid assets), repurchase agreements and securities lending. Income generated from these transactions is paid into the UCITS. Costs generated by these transactions are incurred by the UCITS.

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Significant events during the financial period

01 february 2019 Modification Summary of the management offer: tableau (6,1) Primary market 1 unit(s)
Secondary market 1 unit(s.)

01 february 2019 Ajout 3. Derivatives: tableau (1,0) futures: on equities and indices.

01 february 2019 Ajout 3. Derivatives: tableau (1,1) futures: on equities and indices.

01 february 2019 Ajout 3. Derivatives: tableau (1,3) options : on bonds and indices.

01 february 2019 Ajout 3. Derivatives: tableau (1,4) options: on equities and indices.

01 february 2019 Ajout 3. Derivatives: tableau (1,6) options : sur equities, currencies and indices.

01 february 2019 Ajout 3. Derivatives: tableau (1,7) total return swaps: on bonds and indices. The Fund may enter into exchange contracts in two combinations from the following types of flows: - fixed rate - variable rate (indexed on the Eonia, Euribor, or any other market benchmark) - performance linked to one or more listed currencies, equities, stock market indices or securities, UCIs or investment funds - dividends (net or gross).

01 february 2019 Ajout 3. Derivatives: tableau (1,8) total return swap: on bonds and indices. The Fund may enter into exchange contracts in two combinations from the following types of flows: - fixed rate - variable rate (indexed on the Eonia, Euribor, or any other market benchmark) - performance linked to one or more listed currencies, equities, stock market indices or securities, UCIs or investment funds - dividends (net or gross).

01 february 2019 Ajout 3. Derivatives: tableau (1,10) total return swap:

01 february 2019 Modification Subscription and redemption in the primary market: On the primary market, new Fund units are subscribed and/or redeemed in return for (i) cash or (ii) in-kind contribution/withdrawal of a basket of equities representative of the composition of the MSCI Europe Health Care Index complete with a "cash adjustment". In this market, initial subscriptions are only allowed in minimum quantities of 6000 units and subsequent subscriptions are only allowed in minimum quantities of one unit. Redemptions are made in whole units, with a minimum value of EUR 500,000 or equivalent in the currency of the unit per redemption request. Orders for the subscription and redemption of Fund units are cleared on a daily basis by the Depositary, between 09: 00 and 17: 00 (Paris time), on days when the Paris Stock Exchange is open (the "Trading Day"). Subscription and redemption requests sent after 17: 00 (Paris time) on a Trading Day will be processed as orders received between 09: 00 and 17: 00 (Paris time) on the next Trading Day. A Trading Day is a working day on which the Fund's NAV can be calculated and published. The Fund's NAV on a given trading day is calculated using the closing level of the euro-adjusted MSCI Europe Health Care Index on that day. The exchange rate used to convert the value of the MSCI Europe Health Care Index into euros is the WM Reuters reference rate at the final 16: 00 GMT fixing on that day. Subscriptions/redemptions in cash only Cash-only orders centralised by the Depositary between 09: 00 and 17: 00 (Paris time) on a given Trading Day will be executed on the basis of the net asset value of that same Trading Day. Subscriptions/redemptions made by contributions/withdrawals to/from a portfolio of equities representing the composition of the MSCI Europe Health Care Index Orders centralised by the Depositary between 09:00 and 17: 00 (Paris time) on a given Trading Day will be executed on the basis of the terms set by the Management Company at 17: 00 (Paris time) on the same Trading Day, as follows: (1) contribution of a portfolio of equities reflecting the MSCI Europe Health Care Index as determined by the Management Company, which the subscriber must deliver, and, where applicable, (2) payment of a cash amount in euros to or from the Fund ("cash adjustment") where a subscription/redemption order is for a minimum initial subscription of exactly 6000 units and a minimum subsequent subscription of one unit. Redemptions are made in whole units, with a minimum value of EUR 500,000 or equivalent in the currency of the unit per redemption request. The cash adjustment will be equal to the difference in euros between the net asset value of the Fund units on that date and the value in euros of the equities to be delivered on that date.

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

01 february 2019 Ajout Administrative and management fees: : tableau (0,2) Performance fees.

01 february 2019 Ajout Administrative and management fees: : tableau (1,2) Net assets.

01 february 2019 Ajout Administrative and management fees: : tableau (2,2) None.

01 february 2019 Ajout Administrative and management fees: : tableau (0,3) Turnover commissions:
Received by the Depositary.

01 february 2019 Ajout Administrative and management fees: : tableau (1,3) Levied on each transaction or
operation.

01 february 2019 Ajout Administrative and management fees: : tableau (2,3) None.

01 february 2019 Ajout Administrative and management fees: : tableau (0,4) Charged by the Management
Company on foreign exchange transactions and by Amundi Intermediation on any other instrument.

01 february 2019 Ajout Administrative and management fees: : tableau (1,4) Levied on each transaction or
operation.

01 february 2019 Ajout Administrative and management fees: : tableau (2,4) None.

01 february 2019 Ajout Prospectus updated on: 01 February 2019 Prospectus updated on: 01 February
2019.

01 february 2019 Modification Summary of the management offer: Invest. min. souscr. ultérieures 1.

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Specific details

Voting rights

In accordance with the Fund's Rules and the Fund Manager's stated policy, the Fund Manager exercises the voting rights attached to the securities held by the Fund and decides on contributions in the form of securities, except where the securities are those of the Fund Manager itself or of any associate company as defined in Art L. 444-3 of the French Labour Code (Code du Travail).

Two documents, "Voting Policy" and "Report on the Exercise of Voting Rights", prepared by the Fund Manager in compliance with the current regulations are available upon request.

This mutual fund (OPC) has not been selected as one of the funds which currently exercise voting rights.

Soft commissions

The Fund Manager has received no "soft" commissions.

Movement commission

The Fund Manager has received no commissions on trade.

Use of credit derivatives

The Fund has not used credit derivatives during the period under consideration.

Group funds

Details of the financial instruments held by the Fund which are issued by the Fund Manager or its associates will be found in the Auditor's Report for the latest financial period (enclosed herein) under the following headings of annuals accounts:

- Further details.
- Group financial instruments held by the Fund.

Calculating overall risk

- Overall risk calculation method: the mutual fund uses the commitment calculation method to calculate the mutual fund's overall exposure to financial contracts.

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Regulatory informations

Financial intermediary selection procedure

The Broker Selection Policy draws up and implements a policy which enables it to comply with the Fund's obligation under Art.314-75 (iv) while meeting the requirements set out in Art L.533-18 of the French CMF. For each class of instrument, the policy selects the organizations that will be commissioned to execute orders.

AMUNDI execution policy may be consulted on the AMUNDI website.

Investment advice service

The Fund Manager has not prepared a "Report on Brokerage Expenses" since it has not used any investment advice services.

Information on environmental, social and governance quality criteria (ESG)

- Amundi produces an ESG analysis by rating around 6,000 companies worldwide. The rating scales from A (for issuers with best ESG practices) to G (for worst ESG practices). This analysis is completed by an active engagement policy with issuers, particularly on major sustainable development issues specific to their sector.

- Amundi applies a targeted exclusion policy based on texts with a universal scope such as the United Nations' Global Compact, on human rights and environmental conventions and on the International Labour Organization. Amundi therefore excludes from all its active management*, companies that do not comply with its ESG policy, with international conventions, or with national law and regulations:

- anti-personnel mines,
- cluster munitions,
- chemical weapons,
- biological weapons,
- depleted uranium weapons.

Those issuers have a G rating on Amundi's rating scale.

- Amundi has also decided to exclude or underweight in its portfolios certain issuers whose activities have very strong negative externalities exposing them to increasing societal and regulatory pressures. At the end of 2018, this evolution affects two sectors:

- Coal: exclusion of companies that derive over 25% of their revenue from coal extraction or that produce more than 100m tons of coal each year;
- Tobacco: companies that generate more than 10% of their revenue in the tobacco sector cannot have an ESG rating higher than E (suppliers, manufacturers and retailers).

Additional information on Amundi's methods for incorporating ESG criteria is available on its website: www.amundi.com.

** Except for index funds and ETFs – Exchange Traded Funds – constrained by their benchmark index*

Eligibility for PEAs (French personal equity plans)

In accordance with the provisions of Article 91, section L, of the French General Tax Code, at least 75% of Fund's assets are invested at all times in the securities and rights referred to in Article L.221 31, Section I, sub-section I°, paragraphs a, b and c, of the French Monetary and Financial Code.

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Remuneration policy

1. Remuneration policy and practices of the AIFM/Management company

The remuneration policy implemented by Amundi Asset Management (« Amundi AM ») is compliant with the rules in terms of remuneration specified in the Directive 2011/61/UE of the European Parliament and of the Council of June 8th 2011 on Alternative Investment Fund Managers (the “AIFM Directive”), and in the Directive 2014/91/UE of July 23rd 2014 on undertakings for collective investment in transferable securities (the “UCITS V Directive”). These rules, about remuneration policies and practices, have for objective to promote sound and effective risk management of fund managers and the funds they manage.

This policy is incorporated within the framework of the remuneration policy of Amundi reviewed each year by its Remuneration Committee. The Remuneration Committee approved the remuneration policy in relation to the 2017 fiscal year and its compliance with the AIFM/UCITS Directives’ principles at its meeting held on February 1st 2018. The policy applicable for the 2017 exercise has been reviewed during the Remuneration Committee held on February 1st 2018 and extended in 2018.

In 2018, the implementation of the Amundi remuneration policy was subject to an internal, central and independent audit, driven by the Amundi Internal Audit.

1.1 Amounts of remuneration paid by the Management companies to its employees

During fiscal year 2018, the total amount of compensation (including fixed, deferred and non-deferred bonus) paid by Amundi AM to its employees (1 411 beneficiaries at December 31st 2018) is EUR 143 058 248. This amount is split as follows:

- The total amount of fixed remuneration paid by Amundi AM in 2018: EUR 104 960 035, which represents 73% of the total amount of compensation paid by Amundi AM to its staff, were in the form of fixed remuneration.
- The total amount of bonus deferred and non-deferred paid by Amundi AM in 2018: EUR 38 098 212, which represents 27% of the total amount of compensation paid by Amundi AM to its staff, were in this form. The entire staff is eligible for variable compensation.

Additionally, some ‘carried interest’ was paid by Amundi AM with respect to fiscal year 2018, and is taken into account in the total amount of bonus referred to here above.

Of the total amount of remuneration (fixed and bonus deferred and non-deferred) paid during the fiscal year, EUR 11 282 172 were paid to the ‘executives and senior managers’ of Amundi AM (24 beneficiaries at December 31st 2018), and EUR 11 876 785 were paid to the ‘senior investment managers’ whose professional activities have a material impact on Amundi AM’s risk profile (40 beneficiaries at December 31st 2018).

1.2 Alignment of remuneration policy and practices with risk profile of the AIFs/UCITS

The Amundi Group has adopted and implemented remuneration policy and practices compliant with the latest norms, rules, and guidelines issued from the regulatory authorities for its management companies (AIFM/UCITS).

The Amundi Group has also identified all of its ‘Identified Staff’, which includes all the employees of the Amundi Group having a decision authority on the UCITS/AIFM management companies or the UCITS/AIFs managed and consequently likely to have a significant impact on the performance or the risk profile.

The variable remuneration awarded to the Amundi Group staff takes into account the performance of the employee, its business unit and the Amundi Group as a whole, and is based on financial and non-financial criteria as well as the respect of sound risk management rules.

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

The criteria taken into account for performance assessment and remuneration award depends on the nature of the employee's functions:

1. Management and selection of AIFs/UCITS functions

Common financial criteria:

- Gross and net performance over 1, 3 years ;
- Information ratio and Sharpe ratio over 1, 3 and 5 years ;
- Performance fees collected during fiscal year when relevant ;
- Competitive ranking ;
- Contribution to net inflows/Successful requests for proposals, mandates during fiscal year.

Common non-financial criteria:

- Respect of internal rules in terms of risk management and prevention (Risk/Compliance) ;
- Innovation / Product development;
- Sharing of best practices and collaboration between employees ;
- Commercial engagement ;
- Quality of management.

2. Sales and marketing functions

Common financial criteria:

- Net inflows ;
- Revenues ;
- Gross inflows; client base development and retention; product mix;

Common non-financial criteria:

- Joint consideration of Amundi's and clients' interests ;
- Clients satisfaction and quality of relationship ;
- Quality of management ;
- Securing/developing the business ;
- Cross-functional approach and sharing of best practices ;
- Entrepreneurial spirit.

3. Control and support functions

For control and support functions, performance assessment and remuneration award are independent from the performance of the business they oversee.

Common criteria taken into account are:

- Mainly criteria related to the meeting of objectives linked to their functions (risk management, quality of controls, completion of projects, tools and systems improvement etc.)
- When financial criteria are used, these are mainly related to management/ optimization of expenses.

The above-mentioned performance criteria, and specifically those applicable to Identified staff in charge of the management of AIFs/UCITS, comply with the applicable regulation as well as to the AIF's/UCITS investment policy. These internal rules of Amundi Group contribute to a sound and effective risk management.

Furthermore, Amundi Group has adopted and implemented, for its entire staff, measures aiming to align remuneration with long-term performance and risks in order to avoid conflicts of interest.

In this respect, notably:

- The deferral policy has been adapted to comply with the AIFM and UCITS V Directives' requirements.
- The deferred portion of bonus for identified staff members is awarded in financial instruments indexed at 100% on the performance of a basket of AIFs and/or UCITS funds managed.
- The actual payment of the deferred portion is linked to the financial situation of Amundi Group, with the continued employment within the group and to a sound and effective risk management over the vesting period.

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Certificate drafted by the Auditor on the annual accounts



**STATUTORY AUDITOR'S REPORT
ON THE FINANCIAL STATEMENTS
For the year ended 29 March 2019**

AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF
UCITS CONSTITUTED AS A *FONDS COMMUN DE PLACEMENT*
Governed by the French Monetary and Financial Code (*Code monétaire et financier*)

Management company
AMUNDI ASSET MANAGEMENT
90, rue Pasteur
75015 Paris
France

Opinion

In compliance with the assignment entrusted to us by the management bodies of the management company, we conducted an audit of the accompanying financial statements of AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF, a UCITS constituted as a *fonds commun de placement*, for the year ended 29 March 2019.

In our opinion, the financial statements give a true and fair view of the assets and liabilities and of the financial position of the fund at 29 March 2019 and of the results of its operations for the year then ended, in accordance with French accounting principles.

Basis of our opinion

Audit standards

We conducted our audit in accordance with professional standards applicable in France. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. Our responsibilities under these standards are described in the section "*Statutory Auditor's responsibilities for the audit of the financial statements*" in this report.

Independence

We conducted our audit engagement in accordance with the applicable rules on independence, from 31 March 2017 and up to the date of this report, and in particular we did not provide any non-audit services prohibited under Article 5, paragraph 1 of Regulation (EU) No. 537/2014 or by the auditors' professional code of ethics.

Justification of our assessments - Key audit matters

In accordance with the requirements of articles L.823-9 and R.823-7 of the French Commercial Code (*Code de commerce*) relating to the justification of our assessments, we bring to your attention the key matters as regards to the risk of material misstatement that, in our professional judgement, were the most significant for the audit of the financial statements and our responses to these risks.

These assessments were made as part of our audit of the financial statements, taken as a whole, and therefore contributed to the opinion we formed which is expressed above. We do not provide an opinion on individual items in the financial statements.

Key audit matters	Audit response to cover these risks
<p>The main risks of the fund relate to the financial instruments in its portfolio.</p> <p>Any error in recording or valuing these financial instruments could lead to a misstatement in the calculation of the fund's net asset value and in the financial statements.</p> <p>We therefore focused our work on the existence and valuation of the financial instruments in the portfolio.</p> <p>Valuation of financial instruments traded on a regulated or equivalent market</p> <p>Valuation of the fund's financial instruments traded on a regulated or equivalent market is not complex as it is based primarily on listed prices provided by independent sources.</p> <p>However, the related amounts are significant and could lead to a material misstatement.</p> <p>The value of the financial instruments traded on a regulated or equivalent market is recorded in the balance sheet and presented in the detailed portfolio provided in the notes to the financial statements. The valuation rules for these financial instruments are disclosed in the "Significant accounting policies" note to the financial statements.</p>	<p>We compared the year-end valuation of the fund's financial instruments traded on a regulated or equivalent market with observable prices obtained from market databases.</p>

PricewaterhouseCoopers Audit, 63, rue de Villiers 92208 Neuilly-sur-Seine Cedex, France
T: +33 (0) 1 56 57 58 59, F: +33 (0) 1 56 57 58 60, www.pwc.fr

Key audit matters	Audit response to cover these risks
<p>Valuation of financial contracts traded over the counter</p> <p>As part of its investment strategy, the fund uses over-the-counter swaps. The valuation of these swaps is not observable on a regulated or equivalent market. The valuation of over-the-counter swaps is therefore a key audit matter.</p> <p>The value of the swap is recorded under the line item "financial contracts" in the balance sheet and presented in the detailed portfolio provided in the notes to the financial statements. The commitment related to the swap is presented in the off-balance sheet statement. The valuation rules for these financial instruments are disclosed in the "Significant accounting policies" note to the financial statements.</p>	<p>We verified that the swap's valuation as recorded at year-end agreed to the value communicated by the counterparty to the swap.</p> <p>We gained an understanding of the internal control procedure performed by the management company over swaps valuation. We verified that this procedure had been applied at year-end.</p>
<p>Existence of financial instruments</p> <p>The portfolio's financial instruments are held in custody or maintained by the fund's depository. The depository certifies the existence of financial instruments at year-end.</p> <p>There is nonetheless a risk that these financial instruments could be inaccurately or only partially recorded in the fund's accounting.</p> <p>The existence of these financial instruments is a key audit matter as the related amounts are material and could lead to a material misstatement.</p>	<p>We verified the existence of the portfolio's financial instruments by reviewing the fund's reconciliation between the fund's financial instruments held at year-end and these identified by the depository in an account opened in the fund's name. Any material differences were examined, if applicable using trade tickets or contracts.</p>

Verification of the management report and other documents addressed to unit-holders

In accordance with professional standards applicable in France, we have also performed the specific verifications required by French law.

We have no matters to report as to the fair presentation and the consistency with the financial statements of the information given in the management report, and in the documents addressed to the unit-holders with respect to the financial position and the financial statements.

PricewaterhouseCoopers Audit, 63, rue de Villiers 92208 Neuilly-sur-Seine Cedex, France
T: +33 (0) 1 56 57 58 59, F: +33 (0) 1 56 57 58 60, www.pwc.fr



Disclosures arising from other legal and regulatory requirements

Appointment of the Statutory Auditors

We were appointed as Statutory Auditor of AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF, a UCITS constituted as a *fonds commun de placement*, by the management company on 27 October 2008.

At 29 March 2019, our firm was in the tenth consecutive year of its engagement, i.e. the tenth year following the admission of the fund's securities for trading on a regulated market.

Responsibilities of management and those charged with governance for the financial statements

It is the management company's responsibility to prepare the fund's financial statements presenting a true and fair view in accordance with French accounting principles and to implement the internal control that it deems appropriate for the preparation of financial statements that do not contain material misstatements, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the fund's ability to continue as a going concern, disclosing in the financial statements, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the fund or to cease operations.

It is the management company's responsibility to monitor the preparation of financial information and oversee the efficiency of the internal control and risk management system and the internal audit system relating to the preparation and processing of financial and accounting information.

These financial statements have been prepared by the management company.

Statutory Auditor's responsibilities for the audit of the financial statements

Audit purpose and approach

It is our responsibility to prepare a report on the financial statements. Our objective is to obtain reasonable assurance about whether the financial statements, taken as a whole, are free of material misstatement. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with professional standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As indicated in article L.823-10-1 of the French Commercial Code, our statutory audit of the financial statements is not to guarantee the viability or the quality of your management.

PricewaterhouseCoopers Audit, 63, rue de Villiers 92208 Neuilly-sur-Seine Cedex, France
T: +33 (0) 1 56 57 58 59, F: +33 (0) 1 56 57 58 60, www.pwc.fr

Société d'expertise comptable inscrite au tableau de l'ordre de Paris - Ile de France. Société de commissariat aux comptes membre de la compagnie régionale de Versailles. Société par Actions Simplifiée au capital de 2 510 460 €. Registered office: 63 rue de Villiers 92200 Neuilly-sur-Seine. RCS Nanterre 672 006 483. TVA n° FR 76 672 006 483. Siret 672 006 483 00362. Code APE 6920 Z. Bureaux : Bordeaux, Grenoble, Lille, Lyon, Marseille, Metz, Nantes, Nice, Paris, Poitiers, Rennes, Rouen, Strasbourg, Toulouse.



As part of an audit conducted in accordance with professional standards applicable in France, the Statutory Auditor uses professional judgement throughout the entire audit.
He also:

identifies and assesses the risks of material misstatement of the financial statements, whether due to fraud or error, designs and performs audit procedures responsive to those risks, and obtains audit evidence that is sufficient and appropriate to provide a basis for his opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;

obtains an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control;

evaluates the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management in the financial statements;

concludes on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the fund's ability to continue as a going concern. Such conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are not provided or inadequate, to issue a qualified opinion or a disclaimer of opinion;

evaluates the overall presentation of the financial statements and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Neuilly sur Seine, date of e-signature

Document authenticated by e-signature
The Statutory Auditor
PricewaterhouseCoopers Audit
Patrick SELLAM

*PricewaterhouseCoopers Audit, 63, rue de Villiers 92208 Neuilly-sur-Seine Cedex,
France T: +33 (0) 1 56 57 58 59, F: +33 (0) 1 56 57 58 60, www.pwc.fr*

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Annual accounts

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Balance sheet - asset in EUR

Balance Sheet on 03/29/19

Portfolio : 730055 AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

	03/29/19	03/29/18
FIXED ASSETS, NET		
DEPOSITS		
FINANCIAL INSTRUMENTS	35,682,918.98	31,632,651.61
Equities and similar securities	35,643,726.14	31,590,819.03
Traded in a regulated market or equivalent	35,643,726.14	31,590,819.03
Not traded in a regulated market or equivalent		
Bonds and similar securities		
Traded in a regulated market or equivalent		
Not traded in a regulated market or equivalent		
Credit instruments		
Traded in a regulated market or equivalent		
Negotiable credit instruments (Notes)		
Other credit instruments		
Not traded in a regulated market or equivalent		
Collective investment undertakings		
General-purpose UCITS and alternative investment funds intended for non-professionals and equivalents in other countries		
Other Funds intended for non-professionals and equivalents in other EU Member States		
General-purpose professional funds and equivalents in other EU Member States and listed securitisation entities		
Other professional investment funds and equivalents in other EU Member States and listed securitisation agencies		
Other non-European entities		
Temporary transactions in securities		
Credits for securities held under sell-back deals		
Credits for loaned securities		
Borrowed securities		
Securities sold under buy-back deals		
Other temporary transactions		
Hedges	39,192.84	41,832.58
Hedges in a regulated market or equivalent		
Other hedges	39,192.84	41,832.58
Other financial instruments		
RECEIVABLES	236,514.32	2,691,040.93
Forward currency transactions		
Other	236,514.32	2,691,040.93
FINANCIAL ACCOUNTS	52.57	54.32
Cash and cash equivalents	52.57	54.32
TOTAL ASSETS	35,919,485.87	34,323,746.86

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Balance sheet - liabilities in EUR

Balance Sheet Liabilities on 03/29/19

Portfolio : 730055 AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

	03/29/19	03/29/18
SHAREHOLDERS' FUNDS		
Capital	25,767,219.68	23,358,372.35
Allocation Report of distributed items (a)	7,494,744.07	7,879,139.95
Brought forward (a)	353,523.60	258,563.18
Allocation Report of distributed items on Net Income (a,b)	1,830,495.88	-744.04
Result (a,b)	216,731.57	113,058.66
Total net shareholders' funds	35,662,714.80	31,608,390.10
* Net Assets		
FINANCIAL INSTRUMENTS		
Transfers of financial instruments		
Temporary transactions in securities		
Sums owed for securities sold under buy-back deals		
Sums owed for borrowed securities		
Other temporary transactions		
Hedges		
Hedges in a regulated market or equivalent		
Other hedges		
PAYABLES	256,771.07	2,715,350.36
Forward currency transactions		
Other	256,771.07	2,715,350.36
FINANCIAL ACCOUNTS		6.40
Short-term credit		6.40
Loans received		
TOTAL LIABILITIES	35,919,485.87	34,323,746.86

(a) Including adjustment

(b) Decreased interim distribution paid during the business year

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Off balance sheet in EUR

Off-balance sheet on 03/29/19

Portfolio : 730055 AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

	03/29/19	03/29/18
HEDGES		
Contracts in regulated markets or similar		
OTC contracts		
Other commitments		
OTHER OPERATIONS		
Contracts in regulated markets or similar		
OTC contracts		
Performance swap		
BNP PARIBAS 30.11.20	32,368,009.80	31,019,196.35
Other commitments		

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Income statement in EUR

Income Statement on 03/29/19

Portfolio : 730055 AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

	03/29/19	03/29/18
Revenues from financial operations		
Revenues from deposits and financial accounts		
Revenues from equities and similar securities	306,463.59	192,976.02
Revenues from bonds and similar securities		
Revenues from credit instruments		
Revenues from temporary acquisition and disposal of securities		
Revenues from hedges		
Other financial revenues		
TOTAL (1)	306,463.59	192,976.02
Charges on financial operations		
Charges on temporary acquisition and disposal of securities		
Charges on hedges		
Charges on financial debts	1.71	0.24
Other financial charges		
TOTAL (2)	1.71	0.24
NET INCOME FROM FINANCIAL OPERATIONS (1 - 2)	306,461.88	192,975.78
Other income (3)		
Management fees and depreciation provisions (4)	92,305.35	97,647.02
NET INCOME OF THE BUSINESS YEAR (L.214-17-1) (1-2+3-4)	214,156.53	95,328.76
Revenue adjustment (5)	2,575.04	17,729.90
Interim Distribution on Net Income paid during the business year (6)		
NET PROFIT (1 - 2 + 3 - 4 + 5 + 6)	216,731.57	113,058.66

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Notes to the annual accounts

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Accounting rules and methods

The annual accounts have been drawn up in compliance with the requirements of the French Accountancy Rules Committee rules (n°2003-02 as amended) on the Chart of Accounts for mutual funds (*OPCVM*).

General accounting principles apply, viz:

- fair picture, comparability, ongoing business,
- proper practice & trustworthiness
- prudence
- no unreported change in methods from one period to the next.

Revenues from fixed-yield securities are recognized on the basis of interest actually received.

Acquisitions and disposals of securities are recognized of costs.

The accounting currency of the portfolio is the EURO.

The accounting period reported on is 12 months.

ASSET VALUATION RULES:

Financial instruments are initially recognized at historic cost and carried on the Balance Sheet at their current value: this is their latest known market value or, in the absence of a market, is determined by any external means or by recourse to financial models.

Differences between the securities' current values determined as above and their original historic cost are recognized in the accounts as "differences on estimation".

Securities denominated in a currency other than that of the portfolio are valued in accordance with the above principle and then converted into the currency of the portfolio at the exchange rate obtained on the valuation date.

Deposit:

Deposits maturing in three months or sooner are valued according to the linear method.

Equities, bonds and other securities traded in a regulated market or equivalent:

When calculating the NAV, the equities and other securities traded in a regulated market or equivalent are valued based on the day's closing market price.

Bonds and similar securities are valued at the closing price notified by various financial service providers. Interest accrued on bonds and similar securities is calculated up to the date of asset valuation.

Equities, bonds and other securities not traded in a regulated market or equivalent:

Securities not traded in a regulated market are valued by the Fund Manager using methods based on net equity and yield, taking into account the prices retained in significant recent transactions.

Negotiable credit instruments (Notes):

Negotiable credit instruments which are not actively traded in significant amounts are actuarially valued on the basis of a reference rate as specified below, plus any enhancement to represent the issuer's intrinsic characteristics:

Notes maturing in one year's time or less: euro interbank offered rate (Euribor);

Notes maturing in more than one year's time: the prevailing rate on medium-term interest-bearing Treasury notes (BTAN) or, for the longest Notes, on near-term fungible Treasury bonds (OAT).

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Negotiable credit instruments maturing in three months or sooner may be valued according to the linear method.

French Treasury notes are valued using the market rate published daily by the Banque de France.

UCITS held:

UCITS units or shares are valued at the latest known NAV.

Temporary transactions in securities:

Securities held under sell-back deals are carried in Assets under “credits for securities held under sell-back deals” at the amount provided for in the contract, plus accrued interest receivable.

Securities sold under buy-back deals are booked to the buying portfolio at their current value. The corresponding debt is booked to the selling portfolio at the value set in the contract plus accrued interest payable.

Loaned securities are valued at their current value and carried in Assets under “credits for loaned securities” at their current value plus accrued interest receivable.

Borrowed securities are carried in Assets under “borrowed securities” at the amount provided for in the contract, and in Liabilities under “debts for borrowed securities” at the amount provided for in the contract plus accrued interest payable.

Hedges:

Hedges traded in a regulated market or equivalent:

Hedge instruments traded in regulated markets are valued at the day's settlement price.

Hedges not trades in a regulated market or equivalent:

Swaps:

Rate swaps and/or forward currency transactions are valued at their market value according to the price calculated by discounting future interest streams at market interest (and/or exchange) rates. This price is adjusted for default risk.

Index swaps are valued actuarially on the basis of a reference rate provided by the counterparty.

Other swaps are valued at their market value or are estimated as specified by the Fund Manager.

Off-Balance Sheet Commitments:

Firm hedging contracts are stated among “Off-Balance Sheet Commitments” at their market value at the rate used in the portfolio.

Conditional hedges are converted into their underlying equivalents.

Swap commitments are stated at their nominal value, or at an equivalent amount where there is no nominal value.

Management fees:

Management fees are calculated on the nominal capital on each valuation.

These fees are imputed to the fund's Income Statement.

Management fees are paid in full to the Fund Manager, which bears all the fund's operating costs.

The management fees do not include dealing costs.

The percentage of nominal capital charged is 0.25% including taxes

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Allocation of net profit:

The net profit (loss) for the period is the total of interest, arrears, premiums, allotments and dividends, plus income on ready cash, minus management fees and financial dealing costs. Latent or realised capital gains or losses are not counted as revenue; nor are subscription/redemption fees.

The amounts available for distribution are the net profit for the period, plus any sums brought forward, plus or minus the balance of any revenue adjustment accounts relating to the financial period in question.

In accordance with the arrangements published in the Prospectus, the Fund Manager reserves the right either to capitalize or to distribute any or all of the sums available for distribution for the financial period just ended.

Gains and losses:

The net realised gains (deducted from management fees and realised losses) from the financial year will increase the same type of net realised gains from earlier financial years, if the fund hasn't distributed or accumulated its gains and will also increase or reduce the equalization accounts for realised gains.

Appropriation methods for the distributable amounts:

Distributable amounts	Share
Appropriation of the net income	Accumulation and / or distribution and / or carry forward a decision taken by the management
Appropriation of the net realised gains and losses	Accumulation and / or distribution and / or carry forward a decision taken by the management

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Changes in net asset in EUR

Change in net assets on 03/29/19

Portfolio : 730055 AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

	03/29/19	03/29/18
NET ASSETS IN START OF PERIOD	31,608,390.10	32,226,929.64
Subscriptions (including subscription fees received by the fund)	16,998,901.88	19,521,728.74
Redemptions (net of redemption fees received by the fund)	-19,011,954.90	-15,907,402.98
Capital gains realised on deposits and financial instruments	2,928,113.96	6,223,324.40
Capital losses realised on deposits and financial instruments	-5,225,280.03	-2,768,735.93
Capital gains realised on hedges	66,578,249.42	66,011,082.71
Capital losses realised on hedges	-61,836,266.56	-70,038,308.08
Dealing costs		
Exchange gains/losses	123,275.88	-239,989.04
Changes in difference on estimation (deposits and financial instruments)	3,287,768.26	-3,714,040.41
<i>Difference on estimation, period N</i>	3,353,313.22	65,544.96
<i>Difference on estimation, period N-1</i>	-65,544.96	-3,779,585.37
Changes in difference on estimation (hedges)	-2,639.74	198,472.29
<i>Difference on estimation, period N</i>	39,192.84	41,832.58
<i>Difference on estimation, period N-1</i>	-41,832.58	156,639.71
Net Capital gains and losses Accumulated from Previous business year		
Distribution on Net Capital Gains and Losses from previous business year		
Net profit for the period, before adjustment prepayments	214,156.53	95,328.76
Allocation Report of distributed items on Net Income		
Interim Distribution on Net Income paid during the business year		
Other items		
NET ASSETS IN END OF PERIOD	35,662,714.80	31,608,390.10

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

BREAKDOWN OF FINANCIAL INSTRUMENTS BY LEGAL OR COMMERCIAL TYPE

	Amount	%
ASSETS		
BONDS AND SIMILAR SECURITIES		
TOTAL BONDS AND SIMILAR SECURITIES		
CREDIT INSTRUMENTS		
TOTAL CREDIT INSTRUMENTS		
LIABILITIES		
TRANSACTIONS INVOLVING TRANSFER OF FINANCIAL INSTRUMENTS		
TOTAL TRANSACTIONS INVOLVING TRANSFER OF FINANCIAL INSTRUMENTS		
OFF-BALANCE SHEET		
HEDGES		
TOTAL HEDGES		
OTHER OPERATIONS		
Other	32,368,009.80	90.76
TOTAL OTHER OPERATIONS	32,368,009.80	90.76

BREAKDOWN OF ASSET, LIABILITY AND OFF-BALANCE SHEET ITEMS, BY TYPE

	Fixed rate	%	Variable rate	%	Rate subject to review	%	Other	%
Assets								
Deposits								
Bonds and similar securities								
Credit instruments								
Temporary transactions in securities								
Financial accounts							52.57	
Liabilities								
Temporary transactions in securities								
Financial accounts								
Off-balance sheet								
Hedges								
Other operations								

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

BREAKDOWN OF ASSET, LIABILITY AND OFF-BALANCE SHEET ITEMS, BY TIME TO MATURITY

	< 3 Months	%]3 Months - 1 Year]	%]1 - 3 Years]	%]3 - 5 Years]	%	> 5 Years	%
Assets										
Deposits										
Bonds and similar securities										
Credit instruments										
Temporary transactions in securities										
Financial accounts	52.57									
Liabilities										
Temporary transactions in securities										
Financial accounts										
Off-balance sheet										
Hedges										
Other operations										

All hedges are shown in terms of time to maturity of the underlying securities.

BREAKDOWN OF ASSET, LIABILITY AND OFF-BALANCE SHEET ITEMS, BY LISTING OR EVALUATION CURRENCY

	Currency 1 CHF	%	Currency 2	%	Currency 3	%	Currency N Others currencies	%
Assets								
Deposits								
Equities and similar securities	3,468,252.36	9.73						
Bonds and similar securities								
Credit instruments								
Mutual fund units								
Temporary transactions in securities								
Liabilities								
Financial accounts								
Liabilities								
Transactions involving transfer of financial instruments								
Temporary transactions in securities								
Financial accounts								
Off-balance sheet								
Hedges								
Other operations								

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

BREAKDOWN BY ITEMS OF RECEIVABLES AND PAYABLES

	Type	03/29/19
Receivables	Sales deferred settlement	159,951.12
	Coupons and dividends in cash	76,563.20
Total receivables		236,514.32
Payables	Purchases deferred settlement	- 236,514.32
	Management fees	- 20,256.75
Total of Payables		- 256,771.07
Total payables and receivables		- 20,256.75

SHAREHOLDERS' FUNDS

Number of units issued or redeemed

	Units	Value
Units subscribed during the period	75,100	16,998,901.88
Units redeemed during the period	-82,400	-19,011,954.90
Units in circulation at the end of the period	142,595	

SUBSCRIPTION AND/OR REDEMPTION FEES

	Value
Total of subscription and/or redemption fees received	
Total of subscription fees received	
Total of redemption fees received	

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

MANAGEMENT FEES CHARGEABLE TO THE FUND

	03/29/19
Underwriting commission	
Percentage set for fixed management fees	0.25
Cost of functioning and management fees (fixed management fees)	92,305.35
Commission of performance (variable management fees)	
Trailer fees	

COMMITMENTS RECEIVED AND GIVEN

	03/29/19
Guarantees received by the fund	
- including capital guarantees	
Other commitments received	
Other commitments given	

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

FUTHER DETAILS

Stock market values of temporarily acquired securities

	03/29/19
Securities held under sell-back deals	
Borrowed securities	

Stock market values of pledged securities

	03/29/19
Financial instruments pledged but not reclassified	
Financial instruments received as pledges but not recognized in the Balance Sheet	

Group financial instruments held by the Fund

	Isin code	Name of security	03/29/19
Equities			
Bonds			
Notes			
UCITS			
Hedges			
Total group financial instruments			

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

TABLE OF ALLOCATION OF THE DISTRIBUTABLE SHARE OF THE SUMS CONCERNED TO PROFIT (LOSS)

	03/29/19	03/29/18
Sums not yet allocated		
Brought forward	353,523.60	258,563.18
Profit (loss)	216,731.57	113,058.66
Total	570,255.17	371,621.84

	03/29/19	03/29/18
Allocation		
Distribution		
Brought forward	570,255.17	371,621.84
Capitalized		
Total	570,255.17	371,621.84

TABLE OF ALLOCATION OF THE DISTRIBUTABLE SHARE OF THE SUMS CONCERNED TO CAPITAL GAINS AND LOSSES

	03/29/19	03/29/18
Sums not yet allocated		
Net Capital gains and losses Accumulated from Previous business year	7,494,744.07	7,879,139.95
Net Capital gains and losses of the business year	1,830,495.88	-744.04
Allocation Report of distributed items on Net Capital Gains and Losses		
Total	9,325,239.95	7,878,395.91

	03/29/19	03/29/18
Allocation		
Distribution		
Net capital gains and losses accumulated per share	9,325,239.95	7,878,395.91
Capitalized		
Total	9,325,239.95	7,878,395.91

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

TABLE OF PROFIT (LOSS) AND OTHER TYPICAL FEATURES OF THE FUND OVER THE PAST FIVE FINANCIAL PERIODS

	03/31/15	03/31/16	03/31/17	03/29/18	03/29/19
Net assets in EUR	56,059,255.60	34,486,504.91	32,226,929.64	31,608,390.10	35,662,714.80
Number of shares/units	220,427	162,621	138,414	149,895	142,595
NAV per share/unit in EUR	254.3211	212.0667	232.8299	210.8702	250.0979
Net capital gains and losses accumulated per share in EUR	64.79	59.16	50.14	52.55	65.39
Net income Accumulated per share in EUR					
Unit brought forward in EUR on the result	0.88	1.18	1.72	2.47	3.99

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Portfolio listing of financial instruments in EUR

Name of security	Currency	Quantity	Market value	%
Equities and similar securities				
Listed equities & similar securities				
AUSTRIA				
ERSTE GROUP BANK	EUR	7,722	252,972.72	0.71
TOTAL AUSTRIA			252,972.72	0.71
FRANCE				
AIR LIQUIDE PRIME DE FIDELITE	EUR	14,080	1,595,968.00	4.48
AIRBUS SE	EUR	21,516	2,536,736.40	7.11
L'OREAL PRIME DE FIDELITE	EUR	8,664	2,077,627.20	5.83
LVMH (LOUIS VUITTON - MOET HENNESSY)	EUR	8,132	2,666,482.80	7.47
SANOFI	EUR	15,000	1,181,100.00	3.31
TOTAL	EUR	43,473	2,152,782.96	6.04
TOTAL FRANCE			12,210,697.36	34.24
GERMANY				
ADIDAS NOM.	EUR	6,617	1,433,242.20	4.02
BASF SE	EUR	23,404	1,533,664.12	4.30
BAYER	EUR	16,745	964,512.00	2.70
DEUTSCHE TELEKOM AG	EUR	109,376	1,618,217.92	4.54
DEUTSCHE WOHNEN SE	EUR	36,881	1,594,365.63	4.47
FRESENIUS	EUR	22,040	1,096,710.40	3.08
RWE AG	EUR	67,796	1,620,324.40	4.55
SAP SE	EUR	14,656	1,509,568.00	4.23
SIEMENS AG-REG	EUR	16,051	1,539,932.94	4.32
VOLKSWAGEN AG-PREF	EUR	10,964	1,538,468.48	4.31
TOTAL GERMANY			14,449,006.09	40.52
NETHERLANDS				
ASML HOLDING NV	EUR	7,871	1,316,031.20	3.69
KONINKLIJKE AHOLD NV	EUR	56,661	1,344,282.23	3.77
ROYAL PHILIPS	EUR	13,869	503,652.74	1.41
TOTAL NETHERLANDS			3,163,966.17	8.87
SPAIN				
REPSOL	EUR	101,705	1,552,018.30	4.35
TOTAL SPAIN			1,552,018.30	4.35
SWITZERLAND				
NESTLE NOM.	CHF	40,868	3,468,252.36	9.73
TOTAL SWITZERLAND			3,468,252.36	9.73
UNITED KINGDOM				
ROYAL DUTCH SHELL PLC	EUR	19,543	546,813.14	1.53
TOTAL UNITED KINGDOM			546,813.14	1.53
TOTAL listed equities & similar securities traded in a regulated market or equivalent			35,643,726.14	99.95
Total equities & similar securities			35,643,726.14	99.95

UCITS AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF

Portfolio listing of financial instruments in EUR

Name of security	Currency	Quantity	Market value	%
Hedges				
Other hedges				
Other swaps				
BNP PARIBAS 30.11.20	EUR	32,368,009.8	39,192.84	0.11
Total Other SWAPS			39,192.84	0.11
Total other hedges			39,192.84	0.11
Total hedges			39,192.84	0.11
Receivables			236,514.32	0.66
Debts			-256,771.07	-0.72
Financial accounts			52.57	
Net assets			35,662,714.80	100.00

AMUNDI ETF MSCI EUROPE HEALTHCARE UCITS ETF	EUR	142,595 250.0979
----------------------------------------------------	------------	-------------------------

Amundi Asset Management, French “société par actions simplifiée”-SAS. 1 086 262 605 € capital amount
Portfolio management company authorised by the French Financial Market Authority (AMF) under no GP 04 000 036.
Registered office : 90 boulevard Pasteur - 75 015 Paris - France - 437 574 452 trade and companies' register Paris
amundi.com